In Germany, there is little real-world evidence on physicians' choice of oral anticoagulants
(OACs). Our study aimed at assessing preferences for and prescribing patterns of treatment …

We investigated the prevalence of retinal vascular occlusion and intraocular bleeding and
compare their risks in patients undergoing anticoagulant therapy, either with non-vitamin K …

Aims This study aimed to evaluate the performance of HAS‐BLED and ORBIT scores in
predicting bleeding risk among Asian patients with nonvalvular atrial fibrillation (NVAF) …

Aims Acenocoumarol is a vitamin‐K antagonist (VKA) primarily used in certain countries (eg
India, Netherlands, Spain). The half‐life of acenocoumarol is similar to that of non‐VKA oral …

Background Although epistaxis is one of the most common side effects of oral
anticoagulation, it is unclear whether epistaxis rates vary between different oral …

Background: Current guidelines recommended that oral anticoagulants (OACs) should last
for a minimum first 2 months after atrial fibrillation (AF) ablation and the long-term decision of …

Background Little is known how individual time-in-therapeutic-range (TTR) impacts the
effectiveness and safety of warfarin therapy compared to direct oral anticoagulants (DOACs) …

Background: Real-world, observational studies have investigated the safety profile of Direct
Oral Anticoagulants (DOACs) on Major Hemorrhage (MH) used for stroke prevention in Non …

Compared with younger people, elderly people have higher risks for both thrombosis and
bleeding. Furthermore, comorbidities frequently found in elderly patients complicate the …

The new generation of nonvitamin K antagonists are broadly applied for stroke prevention
due to their notable efficacy and safety. Our study aimed to develop a suggestive utilization …